In the Press

Featured
Recent

Koutif Therapeutics Launched to Treat Inflammatory Diseases

CLEVELAND AND PITTSBURGH, September 21, 2017 –  BioMotiv, a drug development accelerator, and the University of Pittsburgh announced the launch of Koutif Therapeutics, which is developing an inhibitor of an E3 ligase (Fbxo3) to treat inflammatory conditions such...

Allinaire Awarded $1.9M in Grant Funding

CLEVELAND and INDIANAPOLIS, September 19, 2017 – Allinaire Therapeutics has been awarded a $1,670,000 Phase II SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) and a $213,000 Discovery Award from the Department of Defense (DOD). The funding...

Nature Features Sujana’s Technology

CLEVELAND, June 5, 2017 – Nature Communications has published the research of Daniel I. Simon, M.D.; Edward Plow, Ph.D.; and Yunmei Wang, Ph.D. – Founders of Sujana Biotech – which describes a novel target for thrombotic disorders that does not...

Cell Features OptiKira’s Technology for Reversing Diabetes

CLEVELAND, April 26, 2017 – OptiKira founders Dr. Feroz Papa (UCSF), Dr. Bradley Backes (UCSF), and Dr. Dustin Maly (University of Washington) have published research showing that direct targeting of IRE1α, using mono-selective KIRA8, reverses autoimmune...

Takeda, HDI Partner to Advance Rare Diseases Treatments

Harrington Discovery Institute (HDI) and Takeda Pharmaceuticals have teamed up to support the translation of research into treatments for rare diseases. The alliance builds on HDI’s model and results in a dedicated rare-disease funding track that will benefit from...

2017 Harrington Prize for Innovation in Medicine Awarded

CLEVELAND, OH – March 15, 2017 The Harrington Discovery Institute and The American Society for Clinical Investigation are pleased to announce that the 2017 Harrington Prize for Innovation in Medicine has been jointly awarded to Daniel J. Drucker, MD of Mt. Sinai...

OptiKira Receives Significant Grant from ALS Association

CLEVELAND, OH – February 9, 2017 OptiKira has been awarded a $498,500 grant to support the development of their platform technology for the treatment of ALS (Lou Gehrig’s disease).  The company’s technology prevents progressive cell death and is...

Allinaire Therapeutics Receives Significant Funding

CLEVELAND, OH – January 26, 2017   Allinaire Therapeutics, a respiratory therapeutics start-up launched by BioMotiv, has recently received new investments from BioCrossroads’ Indiana Seed Fund and Indiana University’s Innovate Indiana Fund. The...